Kymera Therapeutics (KYMR) and Its Competitors Head-To-Head Survey

Kymera Therapeutics (NASDAQ:KYMR) is one of 844 public companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Kymera Therapeutics to related companies based on the strength of its profitability, earnings, risk, analyst recommendations, dividends, valuation and institutional ownership.

Profitability

This table compares Kymera Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-21.22%	-19.21%
Kymera Therapeutics Competitors	-9,054.47%	-198.89%	-30.64%

Analyst Ratings

This is a breakdown of recent ratings for Kymera Therapeutics and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1	2	23	1	2.89
Kymera Therapeutics Competitors	9782	15049	45283	1571	2.54

Kymera Therapeutics currently has a consensus target price of $139.16, suggesting a potential upside of 6.27%. As a group, “Biotechnology” companies have a potential upside of 97.19%. Given Kymera Therapeutics’ peers higher probable upside, analysts plainly believe Kymera Therapeutics has less favorable growth aspects than its peers.

Risk and Volatility

Kymera Therapeutics has a beta of 1.98, indicating that its stock price is 98% more volatile than the S&P 500. Comparatively, Kymera Therapeutics’ peers have a beta of 1.11, indicating that their average stock price is 11% more volatile than the S&P 500.

Institutional & Insider Ownership

47.9% of shares of all “Biotechnology” companies are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by insiders. Comparatively, 12.9% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Kymera Therapeutics and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Kymera Therapeutics	$102.23 million	-$311.35 million	-36.17
Kymera Therapeutics Competitors	$735.77 million	$13.62 million	-10.04

Kymera Therapeutics’ peers have higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Kymera Therapeutics beats its peers on 8 of the 13 factors compared.

About Kymera Therapeutics

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.